Loading...
XNAS
EXEL
Market cap11bUSD
Jun 06, Last price  
43.03USD
1D
1.56%
1Q
11.53%
Jan 2017
188.60%
IPO
207.36%
Name

Exelixis Inc

Chart & Performance

D1W1MN
P/E
22.51
P/S
5.41
EPS
1.91
Div Yield, %
Shrs. gr., 5y
-1.23%
Rev. gr., 5y
17.51%
Revenues
2.17b
+18.49%
75,961,00098,670,000113,470,000117,859,000151,759,000185,045,000289,636,00047,450,00031,338,00025,111,00037,172,000191,454,000452,477,000853,826,000967,775,000987,538,0001,434,970,0001,611,062,0001,830,208,0002,168,701,000
Net income
521m
+150.89%
-84,404,000-101,492,000-86,381,000-162,854,000-135,220,000-92,330,00075,697,000-147,645,000-244,760,000-268,542,000-169,737,000-70,222,000154,227,000690,070,000321,012,000111,781,000231,063,000182,282,000207,765,000521,267,000
CFO
700m
+110.00%
-46,361,000-45,339,000-68,739,000-9,757,000-14,591,000-101,048,000-159,233,000-123,146,000-198,773,000-235,405,000-141,585,000206,296,000165,611,000415,720,000526,956,000208,982,000400,804,000362,614,000333,324,000699,971,000
Earnings
Aug 04, 2025

Profile

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
IPO date
Apr 11, 2000
Employees
1,223
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑002023‑122022‑122021‑122021‑002020‑002018‑122017‑122016‑122016‑00
Income
Revenues
2,168,701
 
1,830,208
13.60%
1,611,062
63.14%
Cost of revenue
1,402,536
1,659,323
1,409,578
Unusual Expense (Income)
NOPBT
766,165
170,885
201,484
NOPBT Margin
35.33%
9.34%
12.51%
Operating Taxes
160,373
49,756
52,070
Tax Rate
20.93%
29.12%
25.84%
NOPAT
605,792
121,129
149,414
Net income
521,267
 
207,765
13.98%
182,282
63.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
(652,033)
(516,930)
47,772
BB yield
6.48%
6.70%
-0.92%
Debt
Debt current
17,659
Long-term debt
381,646
379,888
380,340
Deferred revenue
6,582
Other long-term liabilities
108,895
94,224
61,951
Net debt
(729,630)
(1,344,131)
(1,667,200)
Cash flow
Cash from operating activities
699,971
333,324
362,614
CAPEX
(40,469)
(138,456)
Cash from investing activities
(116,783)
(26,955)
(524,414)
Cash from financing activities
(628,808)
(546,052)
586
FCF
55,072
(150,772)
Balance
Cash
1,111,276
995,302
1,308,468
Long term investments
728,717
756,731
Excess cash
1,002,841
1,632,509
1,984,646
Stockholders' equity
(99,712)
(176,798)
(48,422)
Invested Capital
2,643,633
2,724,878
2,813,211
ROIC
22.92%
4.37%
5.77%
ROCE
30.12%
6.71%
7.29%
EV
Common stock shares outstanding
296,132
321,464
324,556
Price
33.97
 
23.99
49.56%
16.04
-20.08%
Market cap
10,059,604
 
7,711,921
48.14%
5,205,878
-18.43%
EV
9,329,974
6,367,790
3,538,678
EBITDA
794,968
196,602
222,359
EV/EBITDA
11.74
32.39
15.91
Interest
53,743
Interest/NOPBT
26.67%